Treating Patients with Complex Metabolic Conditions


Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) is a late-stage clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, ALLN-177, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.


Year Invested: 2011
Location: Newton, Mass.
Visit: www.allenapharma.com

Recent News

June 19, 2018
Allena Pharmaceuticals Completes Animal Proof-of-Concept Study for ALLN-346, Lead Product Candidate for Hyperuricemia in the Setting of Advanced Chronic Kidney Disease

June 19, 2018
Allena Pharmaceuticals Completes Animal Proof-of-Concept Study for ALLN-346, Lead Product Candidate for Hyperuricemia in the Setting of Advanced Chronic Kidney Disease

June 11, 2018
Allena Pharmaceuticals Appoints Andrew A. F. Hack, M.D., Ph.D., to its Board of Directors

Read More News

Associated Team Members

Robert Tepper, M.D.
Partner